Assurex Health will use the MassArray system with its GeneSight Psychotropic pharmacogenetic test.
The deal, which included $225 million in upfront payments and up to $185 million in milestones, gives Myriad entry into the neuroscience space.
Despite the historical adoption and reimbursement challenges for PGx testing firms, Myriad said it would try to achieve value-based pricing for Assurex's GeneSight test.
The deal will grant Myriad entry into the neuroscience space, and will allow it to use Assurex's existing sales force to market its own mental health tests.
Investors included existing shareholders Sequoia Capital, Claremont Creek Ventures, Cincinnati Children’s Hospital Medical Center, and Mayo Clinic.
Luminex said its technology will enhance the processing speed and capacity of Assurex's tests.
The funds will go toward efforts to drive clinical adoption and further develop Assurex's GeneSight products.
AdvaMedDx, a division of the Advanced Medical Technology Association, announced the election of several new members to its board of directors.
NEW YORK (GenomeWeb News) – AssureRx Health, a neuropsychiatric personalized medicine company, has formed a scientific advisory board, which will guide the company's R&D efforts on pharmacogenomic products.
AssureRx Health, a neuropsychiatric personalized medicine company, has formed a scientific advisory board, which will guide the company's R&D efforts on pharmacogenomic products.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.